Beth Hecht, See Remarks at Xeris Biopharma Holdings, Inc. (XERS), sold 16,667 shares at $7.43 ($124K) on 2026-01-02, disclosed to the SEC on 2026-01-05.
Scheduled sale ($124k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| XERS | SELL | 2026-07-02 | $134K | — | Filing → |
| XERS | SELL | 2026-06-02 | $101K | — | Filing → |
| XERS | SELL | 2026-05-01 | $104K | — | Filing → |